Futura Medical plc (LSE:FUM) said it now expects unaudited revenue for 2025 to come in at £1.7 million, ahead of previous guidance, following continued sales momentum. The company reported net cash of £3.4 million at year end, bolstered by a £2.75 million fundraising completed in November, which has strengthened its balance sheet and liquidity position.
Futura Medical also highlighted additional near-term cash inflows that could further extend its funding runway. These include a potential US$2.5 million milestone payment linked to the prospective grant of a US patent for its lead product, Eroxon, as well as an expected tax credit refund of around £0.3 million. Taken together with ongoing product sales, management said these factors support a projected cash runway through to December 2026. A strategic review of the business is currently under way and is expected to conclude alongside the release of full-year results in mid-April 2026.
Despite the improved revenue outlook and extended cash visibility, the company’s overall profile remains mixed. Investor sentiment has been weighed down by a sharply reduced outlook for FY2025 discussed during the earnings call, alongside the still relatively limited cash runway and weak technical signals in the share price. These concerns are partly offset by a return to profitability in FY2024 and a debt-free balance sheet, although negative free cash flow continues to temper the financial picture.
More about Futura Medical plc
Futura Medical plc is a UK-based consumer healthcare group focused on the research, development and global commercialisation of clinically proven sexual health products. Its flagship product, Eroxon, is the only over-the-counter topical gel treatment for erectile dysfunction and is marketed through multiple distribution partnerships worldwide. The company also has a pipeline that includes WSD4000, targeting impaired sexual response and function in women, an area of significant unmet medical need.
Leave a Reply